Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K., Hussain, M., … Sweeney, C. J. (2022). Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In ANNALS OF ONCOLOGY (Vol. 33, pp. S1171–S1171).

Halabi, S., A. Roy, L. Rydzewska, P. Godolphin, M. K. Parmar, M. Hussain, C. Tangen, et al. “Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” In ANNALS OF ONCOLOGY, 33:S1171–S1171, 2022.

Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MK, Hussain M, et al. Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In: ANNALS OF ONCOLOGY. 2022. p. S1171–S1171.

Halabi, S., et al. “Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” ANNALS OF ONCOLOGY, vol. 33, no. 7, 2022, pp. S1171–S1171.

Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MK, Hussain M, Tangen C, Thompson IM, Xie W, Carducci MA, Smith M, Morris MJ, Mescam GG, Dearnaley D, Verhagen P, Goto T, James ND, Buyse ME, Tierney J, Sweeney CJ. Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). ANNALS OF ONCOLOGY. 2022. p. S1171–S1171.